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     This study discusses the effect of complexes of chitosan grafted polyethylenimine(Ch-PEI) with plasmid 
DNA on viability of mesenchymal stem cells(MSCs) derived from human marrow. Ch-PEI/pDNA 
nanoparticles were synthesized through the complex coacervation method using pIRES plasmid containing 
Green Fluorescent Protein (GFP) gene. To confirm the complexation, samples were run through an agarose 
gel. Human bone marrow mesenchymal stem cells were studied for the cytotoxicity of the nanoparticles by 
MTT assay. MTT results indicated Ch-PEI does not have any significant cytotoxicity compared with PEI 
and Lipofectamine
2000
 leading to 40% cytotoxicity. According to the results it seems that grafting chitosan 
with PEI improves the MSCs viability. 
 
Keywords: Chitosan; PEI; Cytotoxicity; Mesenchymal stem cell 
 
INTRODUCTION 
     Mesenchymal stem cells are clonogenic and 
nonhematopoeitic cells in bone marrow with the 
ability of differentiating to different mesodermal 
cells such as osteoblast, chondrocyte and 
endothelial cells and even nonmesodermal cells 
such as neurons. They are the first stem cells used 
in clinical application because of their wide 
differentiating potential. Their low 
immunogenecity caused them to be used allogene 
[1]. Transfecting of some genes could lead to a 
better differentiation potential for example 
transfecting of TGF-β gene could lead to 
chondrogenic differentiation or hTERT gene 
could enhance the proliferation [2,3]. But the 
important obstacle is the selection of the best 
procedure for gene transfection. in a perfect gene 
delivery system ,the vector should be nontoxic 
and nonimmunogenic [4], should be small enough 
to enter nucleous [5]. 
Gene delivery vectors divide into two groups: 
Viral and nonviral but the simplest approach is 
using of naked DNA. Direct injection of naked 
DNA in some tissues such as muscle shows a high 
level of expression [6]. Although it causes gene 
expression but its expression level is so less than 
viral or liposomal vectors. Transfection efficiency 
will be higher using viral vectors. But also there 
are some defects that limited their clinical 
application.The first and most important problem 
is patient’s immunity [7]. Viral vectors could only 
transfer small sizes of DNA. They are mutagen 
and oncogen [8,9]. 
Nonviral vectors could be administered frequently 
with minimum immune response. Targetability, 
stability during storage and ease of production are 
some of their advantages [10]. Cationic lipids and 
cationic polymers are the two main types of 
nonviral vectors.They both interact negativley 
charged DNA with electrostatic bonds through 
their positive charge and compose complexes. 
Cationic polymers condense DNA and inhibit 
their degradation by nucleases. The most 
impportant feature is their low toxicity
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contrast with viral vectors they yield lower gene 
expression [11]. chitosan and its derivatives are 
some of cationic polymers [12]. Chitosan is a 
linear aminopolysacharid of N-acetyl-D-glucose 
amine and D-glucose amine [13], biocompatible 
and biodegradable. Chitosan is nonimmunogen 
and low toxic and also can fully protect DNA 
against nucleases [14,15].  
However, its application in biomedical 
experiments is restricted due to its low 
transfection efficiency, it is mainly resulted from 
its 1)low solubility at physiological pH,2) low 
endosomal release resulted from lack of buffering 
amines, and 3) very strong condensation of  DNA 
resulting in inefficient unpackaging of transgene 
in the cytoplasm [16].  
To eliminate these limitations Jiang et al [17] 
prepared Ch-PEI and observed a comparable 
transfection rate of Ch-PEI with that observed 
with Lipofectamine. Thus for a higher level of 
MSCs transfection we proposed  introducing  a 
cationic polymer(PEI) onto the chitosan. This 
grafting circumvents all the limitations (solubility, 
buffering and DNA binding properties) and also 
maintains the integrity of chitosan backbone. 
As per the literature PEI is the most potent 
transfecting agent however, it has high toxicity 
[18]. It is necessary to use a nontoxic vector for 
transfecting target cells In a gene therapy process 
so since there is very rare experiments on gene 
delivery to MSCs by modified chitosan in the 
current experiment we studied the cytotoxicity of 
Ch-PEI nanoparticle as a gene carrier to MSCs. 
 
MATERIAL AND METHODS 
Material 
     MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) (SIGMA), αMEM, 
FBS, Penicillin/Streptomycin (Pen/Strep), 
Trypsin/EDTA (Ethylene Diamine Tetraacetic 
Acid ) (GIBCO), pIRES plasmid and 
Lipofectamine™ 2000( invitrogen ) 
Polyethylenimine and Low molecular weight 
chitosan (75-85% deacetylated)(aldrich ), tris 
base, ethidium bromide, dimethyl sulfoxide 
(MERCK), Qiagene HiSpeed Plasmid Maxi Kit, 





     pIRES plasmid amplification was carried out 
in Escherichia coli DH5α and the purification 
process using Qiagene HiSpeed Plasmid Maxi Kit 
performed according to the manufacturer’s 
instructions. In order to evaluate the concentration 
of purified plasmid DNA absorptiometry at 
260nm was performed. Finally pIRES plasmid 
encoding GFP was alliqouted to the concentration 
of 0.2 μg/μl and stored at -20 ͦ  c. 
Synthesis of Ch-PEI 
   Synthesis was carried out with a process similar 
to Jiang et al [17]. Briefly potassium periodate 
(0.01M) and chitosan (0.1M) were dissolved in 
sodium acetate buffer (pH 4.5), degassed with N2 
and adjusted to 4 ◦C. Reaction left for 48h and 
stopped by ethylene glycol (10% v/v). Then 
dialyzed against NaCl (0.2 M, pH 4.5) and 
deionized water (pH 4.5). 
In the second step PEI (20mM) stirred for 2 days 
at 4 ◦C with the periodateoxidized 
chitosan solution (10mM). Subsequently treated 
with sodium borohydride (2 g) and dialyzed 
against NaCl (0.2 M, pH 4.5) and deionized water 
at 4 ◦C. Finally the product was freeze dried.  
Preparation of the solutions 
1) Chitosan was dissolved in 1% acetic acid and 
was diluted to 1% (V/W) concentrations. PH of 
the solutions was adjusted to 5.5 -5.7.  
2 and 3) PEI and Ch-PEI were dissolved in PBS 
to 1% concentration. Finally each solution was 
filtered through the 0.22µ filters. 
Complex formation 
   Nanoparticles were prepared by using the 
complex coacervation process nearly according to 
what Chew and Gao et al. reported[19,20]. Equal 
volumes of each solution ( Ch, Ch-PEI and PEI) 
and plasmid DNA (0.2 μg/μl concentration) 
warmed to 55°C and rapidly vortexed for 60s. 
Then complexes left for 30 min at room 
temperature to become stable. 
Gel Retardation Assay 
   Naked DNA and different concentrations of Ch-
PEI/pDNA nanoparticles were loaded onto a 0.8% 
agarose gel containing EtBr in Tris-borate EDTA 
buffer. The samples were  
mixed with a loading buffer and run through the 
gel at 80V for 1hour. Finally the gel was stained 
with EtBr and photographed. 
 
 




Isolation and culture 
   Human bone marrow obtained from healthy 
donors after informed consent and diluted with 
PBS and layered onto Ficoll. MSCs were isolated 
from bone marrow in a multi step process. So it 
centrifuged at 1500 rpm for 30 min at 4 .  
Then interphase mononuclear cells were collected 




 in α-MEM 
medium supplemented with 15% fetal bovine 
serum, Pen/Strep(100U/ML) and 2mML-
glutamine and incubated at 37  in a 5% CO2  
humidified atmosphere. Culture medium was 
exchanged 2 times a week and when cells reached 
more than 80% confluency, they were treated with 
0.25% trypsin/ethylene diamine tetra acetic acid 
(EDTA) for 3 min and replaced for subculture. 
The cells were expanded for three passages. 
Osteogenic, Adipogenic, and Chondrogenic 
Differentiation 
   For Osteogenic and Adipogenic  induction cells 
of third passage were seeded at a density of 3000 
cells/cm
2 
and were cultured in αMEM medium 




10mM betaglycerophosphate (Sigma-Aldrich) and 
50 µg/ml ascorbic acid-2-phosphate (Wako 
Chemicals) or adipogenic supplements (1 mM 
dexamethasone and 60 mM indomethacin; Sigma-
Aldrich). Cells were incubated in 37  and 5% 
CO2. Culture medium was changed every 3 days 
for a period of 3 weeks.  
Osteocytes were fixed with methanol at 5 min, 
and treated with Alizarin Red for 2 min and 
washed with H2O. Adipocytes were washed with 
DPBS and fixed in 10% formalin solution and 
finally differentiation was confirmed by oil red 
staining. 
Chondrogenic induction: A micro mass culture 
system was used [21,22]; 2×10
5 
of third passage 
cells were pelleted under 300g for five minutes in 
a 15-ml polypropylene tube. The pellet was 
cultured at 37  with 5% CO2 in 500 µl of 
chondrogenic medium containing 10 ng/ml 
transforming growth factor-β3 (TGF-β3, Sigma, 
Germany) for 3 weeks. The pellets were 
embedded in paraffin and cut into 5-µm sections 
and finally stained with toluidine blue. 
 
Cell viability assay 
   In order to evaluate the effect of ch-PEI/pDNA 
nanoparticles on MSCs viability, 24h prior to 
treatment cells were seeded at 10
4
 cell/well in a 
96 well plate and feeded with 100 μl αMEM 
supplemented with 15% FBS and 0.1% Pen/Strep. 
The next day medium was replaced by fresh 
medium. Subsequently  cells received 
chitosan/DNA nanoparticles containing 1μg  
DNA and incubated  in 37°C and 5%CO2 for 
12hours. Untreated cells used as positive control. 
Lipofectamine also used for comparison of 
viability ratio. At the end of incubation time 
medium was removed and MTT 
solution(5mg/ml)/medium to the ratio of 1/5 
added to the culture and incubated for 2h in 37°C 
and 5%CO2.Then medium was replaced with 100 
μl DMSO. Viability was assesed by absorbance 




   Composition of  nanoparticles through complex 
coacervation process was confirmed by 
retardation of the complexes in agarose gel 
electrophoresis(Fig.1). Naked DNA indicated no 
retardation. Ch ,Ch-PEI and PEI complexes were 
completely retarded in agarose gel indicating the 
neutralization of plasmid DNA negative charge. 
Mesenchymal Stem Cell Isolation and 
differentiation 
   In primary cultures, some cells tended to be 
adhered. These cells of elongated morphology 
proliferated to form colony which then grew 
larger and became confluent(Fig.2) 
The osteogenic culture undergoes mineralization 
following osteogenic differentiation and  
confirmed by alizarin red staining. 
By oil red staining of adipogenic cultures, lipid 
droplets were observed in differentiating cells. 
Toluidin blue staining of the sections prepared 
from chondrogenic pellets demonstrated the 
presence of a metachromatic matrix (Fig.3) 
 






Figure1. Electrophoretic analysis of chitosan, PEI, Ch-




Figure2. Human bone marrow derived mesenchymal 
stem cell culture. A) Bone marrow cell at primary culture. 




Figure3. Human bone marrow derived mesenchymal stem cell differentiation. A) Oil red staining of the adipogenic culture. 
B) The same culture before staining. C) Alizarin red staining of the osteogenic culture. D) The same culture before staining. 
E)Toluidin blue staining of chondrogenic culture 
 







Figure4. (Mean Viability of hMSCs under treatment with naked DNA, lipofectamine and 3 different polyplexes. Untreated 




   The effect of ch-PEI/pDNA complexes on 
MSCs viability was evaluated using MTT assay. 
Cells were treated with nanoparticles under 
experimental condition employed in this paper. 
As shown in Figure 4. 
PEI causes a great cytotoxicity comparable with 
lipofectamine on mesenchymal stem cells. But 
also Ch-PEI at 1% concentration resultet in 
96.35% viability,shows no significant difference 
with Naked DNA. On the other hand results show 
that grafting of PEI to chitosan reduces the 
cytotoxicity of chitosan for 14.5%. 
 
DISCUSSION 
     For the treatment of orthopedic disorders such 
as osteoporosis, arthritis, or bone tumors one of 
the best approaches is to deliver the intact gene to 
the targeted area [23,24]. Here, the combination 
of nanoparticles with an “osteoprotective” gene is 
an obvious strategy. For example, Fernandes et al 
used folate-chitosan nanoparticles in combination 
with an interleukin-1 receptor antagonist (IL-1Ra) 
gene to decrease inflammation and reverse 
alterations in bone turnover in an arthritic rat 
model. But the most important problem of gene 
therapy is to find a biocompatible, non 
immunogenic and efficient gene delivery system 
to protect gene and safely deliver it to the target 
cell. In this regard many nanoparticles used to 
deliver gene to MSCs [25,26]. Nanoparticle-based 
gene therapy offers great opportunities for fine 
modulation and treatment of bone diseases of 
different origin. 
Nanosized complexes are formed upon self-
assembly of negatively charged DNA with 
positive charge of polymer through electrostatic 
interaction, and excessive amine groups 
contribute to the surface positive charge. The 
cationic characteristic of polymer is necessary for 
complex formation and also for the complexes to 
bind to anionic cell surfaces to facilitate cellular 
uptake [27]. 
HMSCs were successfully isolated and cultured to 
form a fibroblast –like morphology and 
differentiation to three mesenchymal lineages 
(adipocytic,osteocytic and chondrocytic). They 
confirmed the mesenchymal stem cells 
characteristics. It was mentioned in our previous 
report that these cells are mononuclear 
nonphagocytic cells with fibroblast-like 
phenotype and colongenic potential capable of 
adhering to the culture surface in a monolayer 
culture [28]. 
One of the most important factors in selection of 
polymeric gene carrier is its Cytotoxic effect on 
the target cells. In this study a combination of two 
different polymeric vectors(chitosan and 
polyethyleneimine) was studied considering their 
cytotoxicity. The cytotoxicity of cationic 
polymers is probably caused by polymer 
aggregation on cell membrane and interactions 
with components [29,30]. Also these polymers 
may interfere with intracellular processes of cells 
 




for example primary amine was reported to 
disrupt protein kinase C function through 
disturbance of protein kinase activity [31]. 
Chitosan is known as biocompatible polymer with 
a low toxic effect. It is an ideal carrier but it’s 
most important deficiency is the poor 
transfection.The biophysical characteristics of 
chitosan/pDNA nanoparticles such as size, zeta 
potential and N/P ratio are the inevitable factors 
for a favorable cellular uptake [32,33]. 
On the other hand, polyethyleneimine could help 
chitosan for a favorable cellular uptake but also it 
has has severe toxicity due to a high density of 
primary amine groups
 
[34] Therefore befor 
administration this derivative of chitosan and PEI 
should be carefully checked for any cytotoxiccity. 
In this experiment Ch-PEI nanoparticles showed 
much higher viability of MSCs than PEI or Ch 
separately. Its low cytotoxicity may be caused by 
the increase in the charge density due to increase 
in the number of primary amine groups [35]. In 
addition, Ch-PEI may degrade into nontoxic PEI 




      Mesenchymal stem cells viability in treatment 
with Ch-PEI nanoparticles shows that these 
nanoparticles could be a promising gene carrier 
gene therapy of bone and cartilage disorders. 
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